通用汽车首席执行官：正努力抵消关税成本。 ...

预计将抵消至少30%的关税风险。 预计北美定价将同比上涨0.5%-1%。 预计2025年邮轮业务将节省约5亿美元。 通用汽车：预计全年调整后每股收益8.25美元至10.00美元，此前预计11美元-12美元。 ...

Strong Execution and Continued Business Agility Q1 2025 Earnings May 1, 2025 Cadillac Escalade 2 Page 4 Business update Page 12 Financial information Page 26 Supplemental financial information Table of contents GMC Sierra EV Information relevant to this presentation GMC Acadia Cautionary Note on Forward-Looking Statements This communication and related comments by management may include "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements are any st ...

通用汽车(GM.N)仍预计今年的资本支出将达到100亿美元至110亿美元。 ...

智通财经5月1日电，通用汽车仍预计今年的资本支出将达到100亿美元至110亿美元。 ...

通用汽车仍预计今年的资本支出将达到100亿美元至110亿美元。 ...

通用汽车表示，目前预计息税前利润将在100亿美元至125亿美元之间，低于1月份最初预期的157亿美 元。根据首席执行官致股东的一封信，原因是该公司受到关税的影响。 ...

金十图示：2025年05月01日（周四）全球汽车制造商市值变化 3 @ JINTO.COM 金十数据 | 一个交易工具 JIN10.COM t w k a station and and a comments of | 宝马汽车 | 520.45 | + -15.54 | 84.04 | | --- | --- | --- | --- | | MS 玛鲁蒂铃木 | 455.79 | 1 +15.46 | 144.97 | | 通用汽车 | 453.57 | + -17.04 | 45.24 | | 保时捷 | 453.35 | + -9.25 | 49.87 | | ( 本田汽车 | 442.04 | + -4.19 | 30.51 | | 马恒达汽车 S | 415.52 | 1 +2.72 | 34.64 | | 福特汽车 | 398.05 | + -5.57 | 10.01 | | 19 现代汽车 | 338.04 | 1 +0.34 | 50.05 | | I 赛力斯 | 292.7 | 1 +7.83 | 17.92 | | 塔塔汽车 | 289.81 | + -9.61 | 7.62 | | 斯特 ...

GROTON, Conn., April 30, 2025 /PRNewswire/ -- General Dynamics Electric Boat, a business unit of General Dynamics (NYSE: GD), announced today it has been awarded a total of $12.4 billion in contract modifications for construction of two fiscal year 2024 Virginia-class submarines. Additionally, the award funds investments to improve productivity at the shipyards and workforce support as detailed in the Department of Defense contract award announcement (https://www.defense.gov/News/Contracts/Contract/Article/ ...

Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of Ma ...